Costs and benefits to the mother of antenatal HIV testing: Estimates from simulation modelling

AIDS

Volumn 13, Issue 12, 1999, Pages 1569-1576

  Gibb, Diana M ^a,d   Ades, A E ^b   Gupta, Ramyani ^b   Sculpher, Mark J ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

Antenatal testing; Health service; Maternal HIV; Modelling; Treatment benefits; Treatment costs

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; SIMULATION; T LYMPHOCYTE; VERTICAL TRANSMISSION;

CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MATERNAL WELFARE; MODELS, STATISTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL DIAGNOSIS; VALUE OF LIFE;

EID: 0032869844     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199908200-00018     Document Type: Article

References (40)

1. Hamers FF, Delmas MC, Alix J. Unawareness of HIV seropositivity before AIDS diagnosis in Europe. XII International Conference on AIDS. Geneva, June1998 [abstract 43105].
2. Briggs A, Gibb D, Sculpher M, MacDonagh SE, Ades AE. Antenatal testing for HIV infection. Developing a model for economic evaluation. HERG Discussion Paper 14: June, 1996 (ISBN 18721 66 679).
3. Ades AE, Davison CF, Holland FJ, et al. Vertically transmitted HIV infection in the British Isles. BMJ 1993, 306:1296-1299.
4. Nicoll A, McGarrigle C, Brady T, et al. Epidemiology and detection of HIV-1 among pregnant women in the United Kingdom: results from national surveillance 1988-1996. BMJ 1998, 316:253-258.
5. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
6. Mocroft A, Youle M, Morcinek J, et al. Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. Royal Free/Chelsea and Westminster Hospital's Collaborative Group. BMJ 1997, 314:409-413.
7. Rogers PA, Whitmore Overton SE, et al. Survival of adults with AIDS in the United Kingdom. Commun Dis Rep CDR Rev 1997, 7:R93-R100.
8. Office of Population Census and Surveys. 1992 Mortality Statistics - General, England and Wales. Series DH1 No 27. London: HMSO; 1994.
9. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients witb advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
10. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Federation National des Centres de Lutte contre le SIDA. AIDS 1997, 11:F101-F105.
11. Cameron DW, Heath Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1997, 351:543-549.
12. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ 1997, 315:1194-1199.
13. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 1996, 348:283-291.
14. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998, 352:314-316.
15. Chancellor JV, Hill AM, Sabin CA, Simpson KM, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. PharmacoEconomics 1997, 12:1-13.
16. British Medical Association, Royal Pharmaceutical Society. British National Formulary, No. 31, London: BMA; 1996.
17. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press; 1997.
18. HM Treasury, Economic Appraisal in Central Government: a Technical Guide for Government Departments, London; HMSO; 1991.
19. Department of Health. Policy Appraisal and Health. London: Department of Health; 1995.
20. Mauskopf JA, Paul JE, Wichman DS, White AD, Tilson HH. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening. JAMA 1996, 276:132-138.
21. Remis RS, Vandal AC. Cost-effectiveness of universal and selective HIV screening of pregnant women in Quebec. Fifth Annual Conference on HIV/AIDS Research in Canada. Winnipeg, June 1995 [abstract 338].
22. Ecker JL. The cost-effectiveness of human immunodeficiency virus screening in pregnancy. Am J Obstet Gynecol 1996, 174:716-721.
23. Le Gales C., Moatti JP. Cost-effectiveness of HIV screening of pregnant women in hospitals of the Paris area. The Paris Tours study group of antenatal transmission of HIV, Group '9 maternites'. Fur J Obstet Gynecol Reprod Biol 1990, 37:25-33.
24. Wilkinson D, Floyd K, Gilks CF. Antiretroviral drugs as a public health intervention for pregnant HIV-infected women in rural South Africa: an issue of cost-effectiveness and capacity. AIDS 1998, 12:1675-1682.
25. Marseille E, Kahn JG, Saba J. Cost-effectiveness of antiretroviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa. AIDS 1998, 12:939-948.
26. Newell ML, Dabis F, Tolley K, Whynes D. Cost-effectiveness and cost-benefit in the prevention of mother-to-child transmission of HIV in developing countries. AIDS 1998, 12:1571-1580.
27. Rahman A, Deyton LR, Goetz MB, Rimland D, Simberkoff MS. Inversion of inpatient/outpatient HIV service utilization: impact of improved therapies, clinician education and case management in the US Department of Veteran Affairs. XII International Conference on AIDS. Geneva, June1998 [abstract 42429].
28. Anis A. The cost effectiveness of successive antiretroviral therapeutic drug regimes for the treatment of HIV/AIDS. XI International Conference on AIDS. Vancouver, July 1996 [abstract 24377].
29. Bartlett JG, Chaisson R, Kerruly J, Moore R. HAART: one of the most cost-effective therapies of the past decade. XI International Conference on AIDS. Vancouver, July 1996 [abstract 24380].
30. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
31. Feinberg MB, Carpenter C, Fauci AS, et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998, 128:1079-1100.
32. Oddone EZ, Cowper P, Hamilton JD, et al. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ 1993, 307:1322-1325.
33. Joint Concorde and Opal Coordinating Committee. Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. AIDS 1998, 12:1259-1265.
34. Del Amo J, Petruckevitch A, Phillips A, et al. Disease progression and survival in HIV-1 infected Africans in London. AIDS 1998, 12:1203-1209.
35. European Collaborative Study. Immunological markers in HIV-infected pregnant women. The European Collaborative Study and the Swiss HIV Pregnancy Cohort. AIDS 1997, 11:1859-1865.
36. Tuomala RE, Kalish LA, Zorilla C, et al. Changes in total, CD4+, and CD8+ lymphocytes during pregnancy and 1 year post-partum in human immunodeficiency virus-infected women. The Women and Infants Transmission Study. Obstet Gynecol 1997, 89:967-974.
37. Brettle RP, Raab GM, Ross A, et al. HIV infection in women: immunological markers and the influence of pregnancy. AIDS 1995, 9:1177-1184.
38. Porter K, Wall PG, Evans BG. Factors associated with lack of awareness of HIV infection before diagnosis of AIDS. BMJ 1993, 307:20-23.
39. Sculpher MJ, Gibb D, Ades AE, Ratcliffe J, Duong T. Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers. AIDS 1998, 12:1371-1380.
40. Ratcliffe J, Ades AE, Gibb D, Sculpher MJ, Briggs AH. Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. AIDS 1998, 12:1381-1388.